Ciro Abbondanza

University of Campania "Luigi Vanvitelli" — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index3.4kcitations105works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(28), Estrogen and related hormone effects(24), Peptidase Inhibition and Analysis(21), Protein Degradation and Inhibitors(21), Epigenetics and DNA Methylation(17)

Publications105 total

siRNA-based therapeutic candidate targeting PRDM2 for inhibition of lung cancer progression
Biomedicine & Pharmacotherapy·2025Open Access
Editor’s Note: c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Clinical Cancer Research·2025Open Access
siRNA-based Therapeutic Candidate Targeting PRDM2 for Inhibition of Lung Cancer Progression
2025· 1 citedOpen Access
Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells
Frontiers in Pharmacology·2024Open Access
Recent Updates on PRDM2 in Colorectal Cancer
Frontiers in Bioscience-Landmark·2024Open Access
Multiple Sclerosis: From the Application of Oligoclonal Bands to Novel Potential Biomarkers
International Journal of Molecular Sciences·2024· 12 citedOpen Access
PRDM2 in Cancer: Deciphering the Molecular Orchestra of a Multifunctional Regulator
Interdisciplinary cancer research·2024
RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer
Journal of Translational Medicine·2023· 12 citedOpen Access
Supplementary Figure 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Table 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Table 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 3 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 8 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Table 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 3 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Suppl. Methods from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
Supplementary Figure 5 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Bruno Moncharmont(17), Nicola Medici(16), Giovanni Alfredo Puca(15), Anna Maria Molinari(11), Amelia Casamassimi(11), Monica Rienzo(11), Vincenzo Nigro(10), Erika Di Zazzo(10), Caterina De Rosa(9), Patrizia Gazzerro(7), Valentina Rossi(6), Antonio Agostino Sinisi(6), Gabriella Castoria(6), Ignazio Armetta(6), Lucia Altucci(5), Giulio Piluso(5), Antimo Migliaccio(5), Maurizio Bifulco(5), Bruno Perillo(4), Angela Belsito(4)